European Journal of Internal Medicine
Volume 16, Issue 8 , Pages 551-560, December 2005

Disseminated intravascular coagulopathy in aortic aneurysms

  • A. Fernandez-Bustamante

      Affiliations

    • Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA
  • ,
  • A. Jimeno

      Affiliations

    • Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    • Corresponding Author InformationCorresponding author. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St. Room 162 A, Baltimore, Maryland 21231 U.S.A. Tel.: +1 410 5025835; fax: +1 410 6149006.

Received 10 February 2005; received in revised form 10 May 2005; accepted 2 June 2005.

Abstract 

Aneurysm-induced disseminated intravascular coagulopathy (DIC) constitutes a rare presentation form of aortic aneurysms. The majority of DIC cases are asymptomatic and this condition is usually diagnosed during the perioperative workup; yet, in a minority of cases, DIC leads to the diagnosis of the vascular abnormality. The management of aneurysm-induced DIC is based both on the treatment of the underlying disorder and on an active scrutiny of the hemodynamic and blood support requirements. Blood replacement therapy should be individualized, guided by the clinical situation of the patient (especially considering the bleeding risk or the presence of hemorrhages), and accompanied by a close monitoring of the coagulation status. Fresh frozen plasma is usually the preferred initial option to replace coagulation factors, but fibrinogen, cryoprecipitates, and platelet concentrates are adequate options in certain contexts. Heparins, both non-fractionated and low-weight molecular types, are the most widely accepted agents for achieving adequate control of the coagulation activation and consumption. Other antithrombotic drugs are under study, including antithrombin III and activated protein C, although only the latter has demonstrated a benefit in terms of survival in a comparative, randomized context. Antifibrinolytic agents such as gabexate mesilate, tranexamic acid, and epsilon-aminocaproic acid (EACA) have been used with conflicting results. These agents may have a role for patients with catastrophic bleeding resistant to other therapeutical options, but their relevance as a first line of treatment is, at present, undefined. An assessment of the multitude of therapeutic approaches available would seem to indicate that there is a lack of standardization in the management of these patients. Multi-center, randomized clinical trials are needed to elucidate the most adequate therapy in this context.

Keywords: Aneurysm, Disseminated intravascular coagulopathy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0953-6205(05)00292-X

doi:10.1016/j.ejim.2005.06.015

European Journal of Internal Medicine
Volume 16, Issue 8 , Pages 551-560, December 2005